



ten23 health® becomes first Sterile Product CDMO to earn B Corp Certification

ten23 health achieves its certification as a B Corporation, recognizing its commitment to social and environmental responsibility and sustainability

Basel, Switzerland, 16.09.2024: ten23 health, the human-centric, sustainable contract development and manufacturing organization (CDMO), and strategic partner for the pharmaceutical industry, is proud to announce its official certification as a B Corporation (B Corp). ten23 health is the first biotech and sterile drug product CDMO in the pharmaceutical sector to achieve B Corp certification, which recognizes its dedication to meeting rigorous standards of social and environmental performance, accountability, and transparency.

This prestigious B Corp certification is a testament to a company that voluntarily meets the highest standards in Environmental, Social and Corporate Governance (ESG). These standards were developed independently and cover a company's impact in key areas including governance, workers, community, environment and customers. The B Corp standards are intentionally set high and are intended to provide recognition for companies leading the sustainable transition of our economy.

"Companies like ours that operate in the pharmaceutical sector are used to the demands of a tightly regulated environment," said Hanns-Christian Mahler, CEO of ten23 health. *"We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to voluntarily achieve ambitious and recognized standards like the B Corp certification. After all, our marketplaces are reliant on top ethical standards to protect the environment, professionals and patients. It is our mission to leave a heart-print related to sustainability for our customers, other CDMOs and our employees alike, and I am proud and happy to see our Fairstainability agenda at ten23 health being validated by becoming a B Corp,"* added Mahler.

"We embarked on our B Corp journey from Day 1 onwards as a start-up, with the firm ambition of creating lasting positive impacts, leading to our B Corp "pending" status with our submission for certification as early in 2022. After two years of dedicated efforts, we are proud to earn this certification, with unique recognition in the Pharmaceutical and CDMO industry," commented Cedric Montagne, Sustainability Expert at ten23 health.

"At ten23 health, our goal is to surpass benchmarks, continuously raising the bar for higher standards and improvement beyond regulatory requirements. This certification is a validation of that commitment," said Alissa Monk, Fairstainability Co-Officer at ten23 health. *"We are proud to have received the certification and hope to inspire other companies and CDMOs to do the same, putting fairness and sustainability as a top priority,"* concluded Carole Schanté, Fairstainability Co-Officer at ten23 health.



As a newly certified B Corp, ten23 health joins a global movement of companies using “*business as a force for good*”. The certification highlights the company’s commitment to fostering a positive impact on its employees, communities, and the environment while maintaining high standards of transparency and ethics in its business practices, as also documented in their annual fairstainability reports: link to the current report [here](#).

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company’s name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i’s Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

About the B Corp certification

B Corp is a prestigious certification for companies that meet rigorous standards of social and environmental performance, accountability, and transparency. Certified by the nonprofit B Lab, this certification evaluates a company’s impact on all stakeholders, including workers, customers, suppliers, communities, and the environment. To achieve the certification, companies must undergo a comprehensive assessment, which includes modifying their legal governing documents to prioritize stakeholder interests alongside profits. This legal commitment ensures that the company considers the broader social and environmental consequences of its decisions. Certified B Corps are also required to publicly disclose their performance in key areas, fostering transparency and trust with consumers. More information here: [B Lab Global Site \(bcorporation.net\)](#)



Media contacts:

ten23 health: Marija Petrovic, marija.petrovic@ten23.health; +41 78 694 87 33

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021

B Lab Switzerland: Giovana Bressan giovana@blab-switzerland.ch; +41 58 510 77 10